NCT06213844View on ClinicalTrials.gov

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

February 15, 2025

Study Completion Date

February 15, 2025

Conditions
Healthy ParticipantsAsthma
Interventions
DRUG

IBI3002

Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1

DRUG

Placebo

Single dose of Placebo, administered subcutaneously on Day 1

Trial Locations (1)

3004

RECRUITING

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY